Rather this than a large shed in Scotland18 Mar 2021 15:32
Avacta the new Glaxo
Glaxo’s rise started with one major blockbuster Zantac,which became the worlds largest selling drug, it helped Glaxo into multi mergers with Wellcome and then Smithkline Beecham.
Avacta has the chance to dwarf Glaxo’s rise in the next few years.
Most Biotech stocks have one maybe two drugs or treatments in their pipeline and are often bought out before they get to market.
Avacta has 34 yes 34 chances of a blockbuster product and they are still coming.
Affimer tech can propel Avacta into Blockbuster sales.
Major Pharms & Diagnostics firms have licences and products with Avacta
Daewoong,Moderna,LG Chem,Bruker,ADC,Point,
Astrea,Mologic,Deepverge,Tufts, the more companies that licence affimers the harder and more costly it will be to buy out Avacta.
Oncology x 11
Ava6000,AVA7500,
AVA028,AVA7000,AVA004
AVA027,AVA3996 plus 4 undisclosed targets
Covid x 5
Affidx, Bams,Elisa,
Saliva,Spitaffidx (You can have that one Big Al)
Mologic combination test.
Plus in house pipe line non-COVID diagnostic tests, which include assays for D-dimer, cortisol, vitamins D and B12 and CRP.
LG Chem x 8
Every RNS states a multi-target deal with LG Chem worth up to $400m.
In the business update $98 million for the 2 below and up to $55m for each new product
So LG Chem has potentially 8 new products.
multi-target collaboration with LG Chem incorporating Avacta's Affimer XT™ serum half-life extension and LG Chem has Affimer PD-L1 inhibitortotalling $98million
The expanded partnership also provides LG Chem with rights to develop and commercialise other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life extension for a range of indications and Avacta could earn an additional $55m in milestone payments for each of these new products.
Daewoong x 2
Gene & stem cell with other targets
Point x 1
radiopharmaceutical prodrug
ADC x 3
three undisclosed cancer targets and provide these to ADC Therapeutics
Moderna x 1
exclusive license agreement with respect to certain Affimer molecules
Astrea x 1
Deepverge x 1
Biokit x 1
Sign In
Follow the stocks
